Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.53

€0.53

-8.930%
-0.052
-8.930%
€1.50

€1.50

 
Latest predictions
-
29.10.20
€1.50
24.04.20
buy
Your prediction

Noxxon Pharma N.v. Stock

Noxxon Pharma N.v. took a tumble today and lost -€0.052 (-8.930%).
The community is currently still undecided about Noxxon Pharma N.v. with 1 Buy predictions and 1 Sell predictions.
With a target price of €1.00 there is a hugely positive potential of 88.679% for Noxxon Pharma N.v. compared to the current price of €0.53.

Pros and Cons of Noxxon Pharma N.v. in the next few years

Pros
?
Shareholder structure
?
Brand
?
Worthwhile Investment for the next years
Cons
?
Conscious of the environment
?
Market Position
?
Growth compared to competition
Tell us your opinion to access the 'Wisdom of the Crowds'

Other discussions about Noxxon Pharma N.v. Stock

New thread Forum

News

NOXXON Announces Initiation of NOX-A12 Manufacturing for Future Clinical Studies: https://mms.businesswire.com/media/20191219005756/en/650596/5/NOXXON_logo_HD2.jpg
NOXXON Announces Initiation of NOX-A12 Manufacturing for Future Clinical Studies


Regulatory News:



NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME)

NOXXON Announces That Data Safety Monitoring Board Validates Further NOX-A12 Dose Escalation in Phase 1/2 Brain Cancer Study: https://mms.businesswire.com/media/20191219005756/en/650596/5/NOXXON_logo_HD2.jpg
NOXXON Announces That Data Safety Monitoring Board Validates Further NOX-A12 Dose Escalation in Phase 1/2 Brain Cancer Study


Regulatory News:



NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME)

NOXXON Publishes Interim 2020 Results: https://mms.businesswire.com/media/20191219005756/en/650596/5/NOXXON_logo_HD2.jpg
NOXXON Publishes Interim 2020 Results


Regulatory News:



NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), released today

NOXXON Announces Completion of 6-month Therapy for Low-dose Cohort in Phase 1/2 Brain Cancer Study of NOX-A12 Plus Radiotherapy: https://mms.businesswire.com/media/20191219005756/en/650596/5/NOXXON_logo_HD2.jpg
NOXXON Announces Completion of 6-month Therapy for Low-dose Cohort in Phase 1/2 Brain Cancer Study of NOX-A12 Plus Radiotherapy


Regulatory News:



NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today

NOXXON Announces Three Additional Clinical Centers to Recruit Patients for NOX-A12 Brain Cancer Trial: https://mms.businesswire.com/media/20191219005756/en/650596/5/NOXXON_logo_HD2.jpg
NOXXON Announces Three Additional Clinical Centers to Recruit Patients for NOX-A12 Brain Cancer Trial


Regulatory News:



NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME)

NOXXON Secures Expanded Capacity and Improved Conversion Conditions for Convertible Bonds From Atlas: https://mms.businesswire.com/media/20191219005756/en/650596/5/NOXXON_logo_HD2.jpg
NOXXON Secures Expanded Capacity and Improved Conversion Conditions for Convertible Bonds From Atlas


Regulatory News:



NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today

NOXXON Presents Final Clinical Data From Phase 1/2 NOX-A12 / Keytruda® Combination Trial in Colorectal and Pancreatic Cancer at the ESMO Virtual Congress 2020


Regulatory News:



NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), presents today a

NOXXON to Present Final Clinical Data From the NOX-A12 / Keytruda® Combination Trial in Colorectal and Pancreatic Cancer at the ESMO Virtual Congress 2020


Regulatory News:



NOXXON Pharma N.V. (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that its poster